The Texas Court of Appeals recently ruled against Greenwich Lifesciences, Inc. in a case concerning a petition for a writ of mandamus. The court's decision affects the company as it seeks to contest trial court orders related to venue issues in an ongoing lawsuit. This ruling is significant because it upholds the trial court's decisions, allowing the case to proceed without delay.
The case, titled In Re Greenwich Lifesciences, Inc., was filed under docket number 01-26-00739-CV. It centers on a dispute between Greenwich Lifesciences and Chris Lentz, who is the real party in interest. The court issued its opinion on August 4, 2026, and the ruling has implications for how venue disputes are handled in Texas courts.
Greenwich Lifesciences, Inc. filed the petition for a writ of mandamus to challenge two specific orders from the trial court. The first order, dated November 18, 2025, denied the company's motion to dismiss the case based on improper venue. The second order, issued on July 7, 2026, denied the company’s motion to reconsider the denial of its motion to dismiss.
The underlying case involves Chris Lentz versus Greenwich Lifesciences, Inc., and is being heard in the 113th District Court of Harris County, Texas, presided over by Judge Rabeea Sultan Collier. Greenwich Lifesciences argued that the trial court's decisions regarding venue were incorrect and sought to have the appellate court intervene.
In its opinion, the Texas Court of Appeals stated, “We conclude that relator has failed to establish it is entitled to mandamus relief, and therefore, the Court denies relator’s petition for writ of mandamus.” The ruling also noted that any pending motions, including Greenwich Lifesciences' emergency motion for temporary relief, were dismissed as moot. This means that the court will not consider those motions further.
The panel of justices that heard the case included Justices Caughey, Johnson, and Dokupil. Their decision reinforces the trial court's authority in determining venue matters, which can significantly affect how cases are litigated in Texas.
This ruling has immediate implications for Greenwich Lifesciences as it prepares for the upcoming trial, which is currently set for November 2, 2026. The court's denial of the mandamus petition means that the company must now proceed with the trial under the existing venue determined by the trial court.
The ruling also highlights the challenges companies face when contesting venue decisions. It suggests that parties seeking to change venue must provide compelling evidence to support their claims. This case may set a precedent for future venue disputes in Texas, indicating that appeals courts may be reluctant to overturn trial court decisions without substantial justification.
Looking ahead, it is unclear if Greenwich Lifesciences will pursue any further legal action in response to this ruling. The company may have the option to appeal the decision, but details were not available in the court filing regarding any potential appeal or related cases. The outcome of the trial, set for November, will likely influence any further legal strategies the company may consider.